|
Manubens A, Paiva B, Gutierrez NC, Fernandez M, Calasanz MJ, Rosinol L, Oriol A, Blanchard MJ, Carrillo E, Benavente C, Martinez-Lopez J, Bargay J, Hernandez MT, de la Rubia J, Gonzalez Y, Paricio M, de Arriba F, Ocio EM, Teruel AI, de la Guia AL, Sirvent M, Gironella M, Sampol A, Arguinano JM, Cabrera C, Alegre A, Granell M, Cabanas V, Nunez-Cordoba JM, Mateos MV, Lahuerta JJ, San Miguel JF, Blade J, Rodriguez-Otero P. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy. Hemasphere. 2025 Apr 24;9(4):e70127. doi: 10.1002/hem3.70127. eCollection 2025 Apr. PubMed PMID: 40276216; PubMed Central PMCID: PMC12020018.
AÑO: 2025; IF: 14.6
|
40276216
|
Cedena MT, Puig N, Paiva B, de la Puerta Rueda JE, Perez-Montana A, Casanova M, Brena Atienza J, Garcia A, de Arriba F, Martinez-Chamorro C, Sirvent M, Blanchard MJ, Alonso Fernandez R, Alvarez Rivas MA, Capote FJ, Garcia-Sanchez R, Perez JJ Sr, Rodriguez-Otero P, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San-Miguel JF. Real-world evidence of measurable residual disease assessment in multiple myeloma. Blood Adv. 2025 Dec 11:bloodadvances.2025018454. doi: 10.1182/bloodadvances.2025018454. Online ahead of print. No abstract available. PubMed PMID: 41380099.
AÑO: 2025; IF: 7.1
|
|
Lakhwani S, Rosinol L, Puig N, Pico-Picos MA, Medina-Gonzalez L, Martinez-Lopez J, Paiva B, Cedena MT, Oriol A, Rios-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, Gonzalez E, Casado LF, Marti JM, Encinas C, De Arriba F, Palomera L, Sampol A, Gonzalez-Montes Y, Motllo C, De La Cruz J, Alonso R, Mateos MV, Blade J, Lahuerta JJ, San-Miguel J, Hernandez MT. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica. 2024 Jun 1;109(6):1909-1917. doi: 10.3324/haematol.2023.284154. PubMed PMID: 38031761; PubMed Central PMCID: PMC11141681.
AÑO: 2024; IF: 7.9
|
|
de Arriba de la Fuente F, Gironella Mesa M, Hernandez Garcia MT, Soler Campos JA, Herraez Rodriguez S, Moreno Belmonte MJ, Regueiro Lopez T, Gonzalez-Pardo M, Casanova Espinosa M, On Behalf Of The Carinae Study Investigators. Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study. Pharmaceuticals (Basel). 2024 Sep 26;17(10):1272. doi: 10.3390/ph17101272. PubMed PMID: 39458913; PubMed Central PMCID: PMC11510635.
AÑO: 2024; IF: 4.8
|
|
Mateos MV, Martinez-Lopez J, Rodriguez Otero P, Gonzalez-Calle V, Gonzalez MS, Oriol A, Gutierrez NC, Rios-Tamayo R, Rosinol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Inigo Rodriguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernandez MT, Lopez Jimenez J, Reinoso-Segura M, Garcia Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Blade J, Lahuerta JJ, San-Miguel JF; Spanish Myeloma Group (GEM-Pethema). Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22. PubMed PMID: 39038268; PubMed Central PMCID: PMC11404760.
AÑO: 2024; IF: 41.9
|